Agios Pharm Stock Analysis

Agios Stock Analysis Notes

About 98.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.18. Some equities with similar Price to Book (P/B) outperform the market in the long run. Agios Pharm recorded earning per share (EPS) of 11.64. The entity had not issued any dividends in recent years. Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. Agios Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 0 people. For more info on Agios Pharm please contact Brian MBA at 617 649 8600 or go to https://www.agios.com.

Agios Pharm Investment Alerts

Agios Pharm Upcoming and Recent Events

Agios Largest EPS Surprises

View All Earnings Estimates

Agios Pharm Environmental, Social, and Governance (ESG) Scores

Agios Stock Institutional Investors

Note, although Agios Pharm's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Agios Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.82 B.

Agios Profitablity

The company has Profit Margin (PM) of 18.46 %, which can signify that it executes well on its competitive strategies and has good control over its expenditures. This is very large. Similarly, it shows Operating Margin (OM) of (11.65) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $11.65.

Management Efficiency

Agios Pharm has return on total asset (ROA) of (0.2047) % which means that it has lost $0.2047 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.5729 %, meaning that it created $0.5729 on every $100 dollars invested by stockholders. Agios Pharm's management efficiency ratios could be used to measure how well Agios Pharm manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Agios Pharm's Return On Tangible Assets are very stable compared to the past year. As of the 21st of March 2025, Return On Assets is likely to grow to 0.43, while Return On Capital Employed is likely to drop (0.28). At this time, Agios Pharm's Total Assets are very stable compared to the past year. As of the 21st of March 2025, Non Current Assets Total is likely to grow to about 732.5 M, while Other Current Assets are likely to drop about 23.7 M.

Technical Drivers

As of the 21st of March, Agios Pharm shows the Risk Adjusted Performance of (0.11), mean deviation of 2.33, and Standard Deviation of 3.27. Agios Pharm technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.

Agios Pharm Price Movement Analysis

Agios Pharm Insider Trading Activities

Agios Pharm Outstanding Bonds

Agios Pharm Predictive Daily Indicators

Agios Pharm Corporate Filings

Agios Pharm Forecast Models

Agios Pharm's time-series forecasting models are one of many Agios Pharm's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Agios Pharm's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Agios Pharm prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Agios shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Agios Pharm. By using and applying Agios Stock analysis, traders can create a robust methodology for identifying Agios entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Agios analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Agios analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Agios Pharm stock analysis indicators help investors evaluate how Agios Pharm stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Agios Pharm shares will generate the highest return on investment. By understating and applying Agios Pharm stock analysis, traders can identify Agios Pharm position entry and exit signals to maximize returns.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Agios Pharm. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Agios Stock, please use our How to Invest in Agios Pharm guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Agios Pharm. If investors know Agios will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Agios Pharm listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Agios Pharm is measured differently than its book value, which is the value of Agios that is recorded on the company's balance sheet. Investors also form their own opinion of Agios Pharm's value that differs from its market value or its book value, called intrinsic value, which is Agios Pharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Agios Pharm's market value can be influenced by many factors that don't directly affect Agios Pharm's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Agios Pharm's value and its price as these two are different measures arrived at by different means. Investors typically determine if Agios Pharm is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Agios Pharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.